"Bifidobacterium animalis or mannose supplementation could serve as adjuncts to existing immunotherapies."
Probiotic Metabolite Unlocks T-Cell Power to Fight Melanoma
Researchers from Southern Medical University in Guangzhou, China, have uncovered a surprising anti-cancer mechanism. A common probiotic, Bifidobacterium animalis, found in fermented dairy products, produces the sugar mannose. This metabolite directly activates the immune system's CD8+ T cells, leading to suppressed melanoma progression in mouse models.
The study, published in the May 2026 issue of Cancer Biology & Medicine, reveals a new link between gut microbes and cancer immunotherapy.
The Discovery
The team isolated five Bifidobacterium species from healthy human stool and screened them for anti-cancer activity. B. animalis proved to be the most potent inhibitor of melanoma cell growth in culture.
In mice with B16-F10 melanoma tumors, oral administration of B. animalis significantly reduced tumor volume and weight. Crucially, this effect was achieved without the bacteria colonizing the tumor tissue itself, pointing to the role of secreted metabolites.
Using size fractionation and metabolomics, the scientists identified mannose as the key bioactive molecule. Drinking water supplemented with just 1% mannose replicated the anti-tumor effects, leading to a notable increase in tumor-infiltrating CD8+ T cells and their production of cytotoxic molecules like granzyme B, interferon-gamma, and tumor necrosis factor-alpha.
Mechanism of Action
"Mannose targets the Hippo-YAP1 axis, which had not been previously linked to microbial metabolites in cancer immunotherapy."
The study details how mannose works at the molecular level:
- Entry: Mannose enters CD8+ T cells via the GLUT1 transporter.
- Pathway Activation: It activates the Hippo signaling pathway.
- Brake Removal: This leads to the phosphorylation and cytoplasmic retention of YAP1, a transcription factor that normally suppresses T-cell effector function. This effectively removes a molecular "brake" on T-cell cytotoxicity.
The result is a more robust and aggressive T-cell response against the tumor.
Synergy with Immunotherapy
When combined with anti-PD-1 therapy, B. animalis produced a synergistic effect, improving tumor control compared to either treatment alone. This suggests the probiotic or mannose could serve as a powerful adjunct to existing checkpoint inhibitors.
Significance and Next Steps
The findings identify the Hippo-YAP1 pathway as a new and promising therapeutic target for enhancing T-cell function. The authors noted they were surprised that mannose could have such a profound effect on T-cell immunity.
Clinical studies are now needed to validate these findings in melanoma patients.
Funding: This work was supported by the National Natural Science Foundation of China and the Guangzhou Science and Technology Project.